Status: Recruiting
Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST
This is a phase 0/1/2, multi-site study to evaluate the MEK inhibitor Selumetinib with the MDM2 Inhibitor APG-115 in patients with Neurofibromatosis Type 1 and pre-malignant and malignant peripheral nerve sheath tumors
Participants needed: 45
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: AeRang KimUpdated: Jul 27, 2026Locations: 2
Eligibility criteria
AGE: Part A and C: ≥ 18 years of age AGE: Part B: ≥12 years (minimum BSA ≥0.55m2... [+28]
A malignancy treated with curative intent and with no known active disease ≥2 ye... [+36]